康华生物：重组六价诺如病毒疫苗启动Ⅰ期临床试验并完成首例受试者入组

Core Viewpoint - The company has officially launched Phase I clinical trials for its recombinant hexavalent norovirus vaccine (Pichia pastoris) in mainland China, marking a significant step in its vaccine development efforts [1] Group 1: Vaccine Development - The recombinant hexavalent norovirus vaccine is developed using genetic engineering technology based on virus-like particles (VLPs) [1] - This innovative vaccine is designed to prevent norovirus infections and the acute gastroenteritis they cause [1] - The vaccine theoretically has the potential to prevent over 90% of norovirus infections and related acute gastroenteritis [1]